A Phase II Clinical Trial of E7820 for Patients With Relapsed/Refractory Myeloid Malignancies With Mutations in Splicing Factor Genes.
Latest Information Update: 16 Jul 2024
At a glance
- Drugs E 7820 (Primary) ; Venetoclax
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Proof of concept; Therapeutic Use
- 03 Jul 2024 Planned End Date changed from 1 Aug 2024 to 1 Aug 2025.
- 03 Jul 2024 Planned primary completion date changed from 1 Aug 2024 to 1 Aug 2025.
- 12 Dec 2023 Status changed to recruiting, according to Trial design presented at the 65th American Society of Hematology Annual Meeting and Exposition